Chen Yudi, Sun Kailv, Chang Jianmin
Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Front Immunol. 2026 Feb 6;17:1651543. doi: 10.3389/fimmu.2026.1651543. eCollection 2026.
Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease of the skin. Novel biologic agents represent a potential therapeutic option. We explore the use of dupilumab in the treatment of BP.
Relevant studies published up to Oct. 20th, 2025 were systematically searched using PubMed, Web of Science, Embase, and Cochrane Library. Proportion rates of complete response and disease control were analyzed to determine treatment effects. Data were quantitatively synthesized using a random-effects meta-analysis. Meanwhile, we also conducted statistics on adverse events.
A total of 587 patients from 24 studies were included. Pooled analysis revealed a complete response rate of 68% (95% CI 60%∼78%) and disease control rate of 95% (95%CI 92%~98%) in BP treated with dupilumab with/without other systemic therapy. Notably, complete response rate achieved 63% (95% CI 49%∼81%) in patients with dupilumab without other systemic therapy. A total of 112 adverse events were reported in 97 patients. Most adverse events were mild and did not lead to treatment discontinuation.
This meta-analysis highlights the efficacy and safety of dupilumab in patients with BP, offering valuable evidence to guide future clinical practice.
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251048550.
大疱性类天疱疮（BP）是最常见的皮肤自身免疫性表皮下大疱病。新型生物制剂是一种潜在的治疗选择。我们探讨度普利尤单抗在BP治疗中的应用。
使用PubMed、Web of Science、Embase和Cochrane图书馆系统检索截至2025年10月20日发表的相关研究。分析完全缓解率和疾病控制率以确定治疗效果。采用随机效应荟萃分析对数据进行定量合成。同时，我们也对不良事件进行了统计。
纳入了来自24项研究的587例患者。汇总分析显示，在接受度普利尤单抗联合或不联合其他全身治疗的BP患者中，完全缓解率为68%（95%CI 60%～78%），疾病控制率为95%（95%CI 92%～98%）。值得注意的是，在未接受其他全身治疗的度普利尤单抗患者中，完全缓解率达到63%（95%CI 49%～81%）。97例患者共报告了112例不良事件。大多数不良事件为轻度，未导致治疗中断。
这项荟萃分析突出了度普利尤单抗在BP患者中的疗效和安全性，为指导未来临床实践提供了有价值的证据。
